Intellia Therapeutics Inc (NASDAQ:NTLA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Other research analysts also recently issued research reports about the stock. Jefferies Group reiterated a “buy” rating and issued a $33.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, August 17th. Leerink Swann initiated coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price target for the company. Wedbush reissued an “outperform” rating and set a $38.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, August 23rd. Finally, Credit Suisse Group AG initiated coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $35.50.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/zacks-investment-research-upgrades-intellia-therapeutics-inc-ntla-to-hold.html

Shares of Intellia Therapeutics (NASDAQ:NTLA) opened at 18.70 on Thursday. Intellia Therapeutics has a one year low of $17.05 and a one year high of $30.40. The company’s 50-day moving average is $20.17 and its 200-day moving average is $22.46. The stock’s market capitalization is $673.11 million.

A number of hedge funds have recently added to or reduced their stakes in NTLA. FMR LLC bought a new stake in Intellia Therapeutics during the second quarter worth $112,182,000. Temasek Holdings Private Ltd bought a new stake in Intellia Therapeutics during the second quarter worth $16,878,000. BlackRock Advisors LLC bought a new stake in Intellia Therapeutics during the second quarter worth $13,146,000. Vanguard Group Inc. bought a new stake in Intellia Therapeutics during the second quarter worth $8,894,000. Finally, Franklin Resources Inc. bought a new stake in Intellia Therapeutics during the second quarter worth $6,405,000.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

5 Day Chart for NASDAQ:NTLA

Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.